Roswell Park experts will share the latest advances in the treatment of blood-related cancers
Roswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, April 23-26.
Highlights of guest presentations from Roswell Park at the meeting include discussion of highly anticipated results from an ongoing clinical trial of a chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma as well as the management of graft versus host disease (GVHD) during the COVID-19 pandemic.
Promising results for a new indication of CAR T-cell therapy for multiple myeloma
Jens Hillengass MD, PhD, Head of Myeloma, will share results from CARTITUDE-2, the first study to use a recently FDA-approved CAR T-cell therapy, ciltacabtagene autoleucel (cilta-cel), in patients with multiple relapsed or refractory myeloma after only one to three prior lines of treatment.
“For the first time, patients on the first lines of treatment have received this CAR-T cell therapy,” explains Dr. Hillengass. “The results of CARTITUDE-2 were very encouraging. A single infusion of cilta-cel produced early and profound responses, with 85% of patients showing a complete response and good tolerance.”
Presentation Details: 73 – Cartitude-2 Updated Results: Sunday, April 24, 4-4:15 p.m. MDT, Salt Palace Convention Center, Ballroom D
Customizing therapy for patients with chronic GVHD
In an ASTCT spotlight session, Nataliya Buxbaum, MD, assistant professor of oncology in the Department of Pediatrics and physician in the Childhood Cancer and Blood Disorders Program at Roswell Park Oishei, will discuss Roswell Park’s work to develop a much-needed pathway to personalized therapy for patients with chronic GVHD, which occurs when transplanted donor immune cells attack healthy recipient cells.
“Although we have several FDA-approved drugs and other therapies that are sometimes effective for some patients with chronic GVHD, finding the right treatment usually requires trial and error,” says Dr. hematopoietic stem cell transplantation. “Sometimes patients end up trying multiple lines of therapy for several months before a significant clinical response is achieved. This remains the main challenge in our field, and it can be overcome with personalized therapy – selecting the right drug for the right patient at the right time.”
Presentation details: Biology of chronic GVHD: what we know and don’t know? Sunday, April 24, 8:45 a.m. MDT, Salt Palace Convention Center, Hall C, PIT Room 1
Impact of COVID-19 and socio-economic disparities on the treatment of blood cancers
In poster sessions on Sunday, April 24 (6:30-7:30 p.m. MDT, Salt Palace Convention Center – Hall A), Muhammad Salman Faisal, MD, member of the Department of Medicine, will present the results of two Roswell Park-directed studies:
- Poster 256 “Socioeconomic and Racial Barriers to Access to CD19 Chimeric Antigen Receptor (CART) T-Cell Therapy” highlights the disparity that currently exists in access to CD19 chimeric antigen receptor (CART) T-cell therapy. CAR T cells based on race or access to adequate health insurance, with African Americans and uninsured patients being much less likely to receive needed treatment.
- Poster 496 “Bamlanivimab monoclonal antibody therapy in patients with graft versus host disease (GVHD) diagnosed with COVID-19 infection” discusses the safety and efficacy of bamlanivimab, a monoclonal antibody that has been granted emergency use authorization for the treatment of mild to moderate COVID-19. 19, in immunocompromised GVHD patients with COVID-19 who had undergone transplantation.